相关实验视频
Updated: Jul 1, 2025

03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
413
在不可切割的局部晚期食道状细胞癌当前和未来的前景 (评论)
Weijia Zhang1, Min Zhu2, Ying Xiang2
1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R. China.
Oncology reports
|March 8, 2024
概括
对于无法切除的局部晚期食道状细胞癌 (ESCC) 的新疗法显示出希望. 与标准化疗放射治疗相比,诱导疗法,免疫疗法和向治疗改善了无进展生存率和整体生存率.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
背景情况:
- 自1999年以来,绝对并发化疗是无法切割的局部晚期食道状细胞癌 (ESCC) 的标准.
- 这种治疗存在局限性,包括~50%的局部失效率和平均总生存期 (OS) 为16.9个月.
- 对于ESCC (T1-3N0-1M0) 的5年OS率仍然很低,约为21%.
研究的目的:
- 提供对治疗不可切割的局部先进ESCC的最新进展的全面概述.
- 讨论ESCC管理中的新兴治疗策略和挑战.
主要方法:
- 临床试验的审查和更新的治疗方式对于不可切除的局部先进的ESCC.
- 分析数据,将新疗法与标准化疗或放射治疗进行比较.
主要成果:
- 诱导疗法,巩固疗法,免疫疗法和向疗法在临床试验中已经证明了长时间的中位数无进展存活率和OS.
- 救援手术可能会为选择的患者提供好处.
结论:
- 新的治疗策略正在为不可切除的局部先进的ESCC发展.
- 需要进一步的研究来克服挑战并优化治疗结果.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Barrett Esophagus-II: Clinical Manifestations and Management
150
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
150
Barrett Esophagus-I: Introduction
96
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
96
Esophageal Strictures-I: Introduction
99
Esophageal strictures involve abnormal narrowing or tightening of the esophagus. They vary in length and severity, ranging from mild constriction to complete obstruction, and are classified as benign (noncancerous) or malignant (cancerous).
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
99
Esophageal Perforation-II: Clinical Manifestations and Management
63
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
Clinical Manifestations:
63

